Atreca Prices Stock Offering at $16 Per Share
11:52AM ET 7/16/2020 MT NewswiresAtreca (BCEL) on Thursday priced a public offering of about 7 million of its Class A common shares and 781,250 of its Class B common shares at $16 per...
Quotes Snapshot > BCEL
Atreca Inc BCEL:NASDAQ
Next Earnings date is expected on
08/11/2020
Last Price$13.05NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/03/20
Today's Change+0.10(0.77%)
Bid (Size)$10.07 (4)
Ask (Size)$15.11 (1)
Day Low / High$12.80 - 13.21
Volume495.8 K
Read more news Recent News
Atreca Proposes Upcoming Stock Sale, Shares Sink 5% in Late Trade
4:09PM ET 7/15/2020 MT NewswiresAtreca (BCEL) was down 5% in extended trading after the biopharmaceuticals company late Wednesday disclosed plans for a public offering of its Class A...
Atreca Joins Hands With Xencor to Develop, Commercialize Antibodies With Potential to Help Kill Tumor Cells
8:38AM ET 7/08/2020 MT NewswiresAtreca (BCEL) and Xencor (XNCR) announced early Wednesday a collaboration and license agreement to research, develop and commercialize T cell-engaging...
Analyst Actions: Canaccord Genuity Lifts Atreca's Price Target to $33 From $23, Keeps at Buy
11:32AM ET 7/01/2020 MT NewswiresAtreca (BCEL) has an average buy rating among analysts, with an average price target of $28. (MT Newswires covers equity, commodity and economic research...
View all Commentary and Analysis
Stocks To Watch: Spotlight On SpaceX, Costco, ASCO And HBO Max
8:43AM ET 5/23/2020 Seeking AlphaAtreca (BCEL) Investor Presentation - Slideshow
3:20PM ET 5/21/2020 Seeking AlphaWeek 21 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
8:19AM ET 5/17/2020 Seeking AlphaWeek In Review: I-Mab Seeking $2 Billion Deal For CD-47 Candidate
3:19AM ET 5/04/2020 Seeking AlphaCompany Profile
Business DescriptionAtreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 450 E Jamie Court South San Francisco, California 94080 |
| Phone | +1.650.595.2595 |
| Number of Employees | 85 |
| President, Chief Executive Officer & Director | John A. Orwin |
| Chief Financial Officer | Herbert C. Cross |
| Chief Technology Officer | Guy Cavet |
| Senior Vice President-Research | Daniel Emerling |
Company Highlights
| Price Open | $13.14 |
| Previous Close | $13.05 |
| 52 Week Range | $9.51 - 29.35 |
| Market Capitalization | $289.7 M |
| Shares Outstanding | 22.2 M |
| Sector | Commercial Services |
| Industry | Miscellaneous Commercial Services | Next Earnings Announcement | 08/11/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$5.67 |
| Beta vs. S&P 500 | N/A |
| Revenue | $961.0 K |
| Net Profit Margin | -3,378.32% |
| Return on Equity | -38.07% |
Analyst Ratings as of 05/15/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |